BACKGROUND AND OBJECTIVE: Muscle atrophy in end-stage renal disease (ESRD) may be due to the activation of apoptotic and proteolytic pathways. We hypothesized that activation of caspase-3 in the skeletal muscle mediates apoptosis and proteolysis during haemodialysis (HD). MATERIALS AND METHODS: Eight ESRD patients were studied before (pre-HD) and during HD and the findings were compared with those from six healthy volunteers. Protein kinetics was determined by primed constant infusion of L-(ring (13)C(6) ) Phenylalanine. RESULTS: Caspase-3 activity in the skeletal muscle was higher in ESRD patients pre-HD than in controls (24966·0 ± 4023·9 vs. 15293·3 ± 2120·0 units, P<0·01) and increased further during HD (end-HD) (37666·6 ± 4208·3 units) (P<0·001). Actin fragments (14 kDa) generated by caspase-3 mediated cleavage of actomyosin was higher in the skeletal muscle pre-HD (68%) and during HD (164%) compared with controls. The abundance of ubiquitinized carboxy-terminal actin fragment was also significantly increased during HD. Skeletal muscle biopsies obtained at the end of HD exhibited augmented apoptosis, which was higher than that observed in pre-HD and control samples (P<0·001). IL-6 content in the soluble fraction of the muscle skeletal muscle was increased significantly during HD. Protein kinetic studies showed that catabolism was higher in ESRD patients during HD compared with pre-HD and control subjects. Muscle protein catabolism was positively associated with caspase-3 activity and skeletal muscle IL-6 content. CONCLUSION: Muscle atrophy in ESRD may be due to IL-6 induced activation of caspase-3 resulting in apoptosis as well as muscle proteolysis during HD.
BACKGROUND AND OBJECTIVE:Muscle atrophy in end-stage renal disease (ESRD) may be due to the activation of apoptotic and proteolytic pathways. We hypothesized that activation of caspase-3 in the skeletal muscle mediates apoptosis and proteolysis during haemodialysis (HD). MATERIALS AND METHODS: Eight ESRDpatients were studied before (pre-HD) and during HD and the findings were compared with those from six healthy volunteers. Protein kinetics was determined by primed constant infusion of L-(ring (13)C(6) ) Phenylalanine. RESULTS:Caspase-3 activity in the skeletal muscle was higher in ESRDpatients pre-HD than in controls (24966·0 ± 4023·9 vs. 15293·3 ± 2120·0 units, P<0·01) and increased further during HD (end-HD) (37666·6 ± 4208·3 units) (P<0·001). Actin fragments (14 kDa) generated by caspase-3 mediated cleavage of actomyosin was higher in the skeletal muscle pre-HD (68%) and during HD (164%) compared with controls. The abundance of ubiquitinized carboxy-terminal actin fragment was also significantly increased during HD. Skeletal muscle biopsies obtained at the end of HD exhibited augmented apoptosis, which was higher than that observed in pre-HD and control samples (P<0·001). IL-6 content in the soluble fraction of the muscle skeletal muscle was increased significantly during HD. Protein kinetic studies showed that catabolism was higher in ESRDpatients during HD compared with pre-HD and control subjects. Muscle protein catabolism was positively associated with caspase-3 activity and skeletal muscle IL-6 content. CONCLUSION:Muscle atrophy in ESRD may be due to IL-6 induced activation of caspase-3 resulting in apoptosis as well as muscle proteolysis during HD.
Authors: Dominic S C Raj; Oladipo Adeniyi; Elizabeth A Dominic; Michel A Boivin; Sandra McClelland; Antonios H Tzamaloukas; Nancy Morgan; Lawrence Gonzales; Robert Wolfe; Arny Ferrando Journal: Am J Physiol Endocrinol Metab Date: 2007-01-30 Impact factor: 4.310
Authors: Biruh T Workeneh; Helbert Rondon-Berrios; Liping Zhang; Zhaoyong Hu; Gashu Ayehu; Arny Ferrando; Joel D Kopple; Huiyun Wang; Thomas Storer; Mario Fournier; Seoung Woo Lee; Jie Du; William E Mitch Journal: J Am Soc Nephrol Date: 2006-09-27 Impact factor: 10.121
Authors: D S C Raj; P Moseley; E A Dominic; A Onime; A H Tzamaloukas; A Boyd; V O Shah; R Glew; R Wolfe; A Ferrando Journal: Kidney Int Date: 2008-02-20 Impact factor: 10.612
Authors: Juan Jesús Carrero; Michal Chmielewski; Jonas Axelsson; Sunna Snaedal; Olof Heimbürger; Peter Bárány; Mohamed E Suliman; Bengt Lindholm; Peter Stenvinkel; Abdul Rashid Qureshi Journal: Clin Nutr Date: 2008-06-06 Impact factor: 7.324
Authors: D S C Raj; M A Boivin; E A Dominic; A Boyd; P K Roy; T Rihani; A H Tzamaloukas; V O Shah; P Moseley Journal: Eur J Clin Invest Date: 2007-12 Impact factor: 4.686
Authors: Michael I Lewis; Mario Fournier; Huiyuan Wang; Thomas W Storer; Richard Casaburi; Arthur H Cohen; Joel D Kopple Journal: J Appl Physiol (1985) Date: 2011-10-20
Authors: Michael I Lewis; Mario Fournier; Huiyuan Wang; Thomas W Storer; Richard Casaburi; Joel D Kopple Journal: J Appl Physiol (1985) Date: 2015-07-16
Authors: Benjamin T Barnes; Amy L Confides; Mark M Rich; Esther E Dupont-Versteegden Journal: J Muscle Res Cell Motil Date: 2015-03-05 Impact factor: 2.698
Authors: Robert H Mak; Alp T Ikizler; Csaba P Kovesdy; Dominic S Raj; Peter Stenvinkel; Kamyar Kalantar-Zadeh Journal: J Cachexia Sarcopenia Muscle Date: 2011-03-16 Impact factor: 12.910
Authors: Maria R Wing; Wei Yang; Valerie Teal; Sankar Navaneethan; Kaixiang Tao; Akinlolu Ojo; Nicolas N Guzman; Muredach Reilly; Melanie Wolman; Sylvia E Rosas; Magda Cuevas; Michael Fischer; Eva Lustigova; Stephen R Master; Dawei Xie; Dina Appleby; Marshall Joffe; John Kusek; Harold I Feldman; Dominic S Raj Journal: Obesity (Silver Spring) Date: 2014-02-11 Impact factor: 5.002